Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292297466> ?p ?o ?g. }
- W4292297466 endingPage "4807" @default.
- W4292297466 startingPage "4792" @default.
- W4292297466 abstract "Treatment options in patients with mantle cell lymphoma (MCL) failing ibrutinib are limited, with no standard therapies defined. This study aimed to investigate real-world treatment patterns and outcomes for patients with MCL following ibrutinib. This study utilized a de-identified hospital-based claims database (Medical Data Vision) in Japan. Eligible patients were adults who were diagnosed with MCL and had received antitumor drugs between December 2010 and July 2020. Patients were followed from the first antitumor drug treatment until the end of available data up to July 2021. Time-to-event analyses utilized the Kaplan–Meier method. Factors for receiving post-ibrutinib therapy were explored with logistic regression analysis. Of the 1386 patients who started antitumor drug therapy, 247 patients received and discontinued ibrutinib at any line of therapy. Among them, 137 patients (55.5%) received subsequent therapy. The median age at the end of ibrutinib therapy was 77 (range 42–95), and 44 patients had a dependent activity of daily living (ADL). Factors negatively associated with receiving post-ibrutinib therapy after discontinuation of ibrutinib were age ≥ 75 years (odds ratio [95% CI] 0.46 [0.26–0.80]) and emergency hospital admissions (0.37 [0.17–0.84]). Immediate post-ibrutinib therapy regimens were highly diverse, with BR (bendamustine, rituximab) only prescribed in more than 10% of patients. The median duration of post-ibrutinib therapy was 1.5 months (95% CI 1.07–2.07). The median overall survival from the end of ibrutinib therapy in patients regardless of the receipt of post-ibrutinib therapy (n = 247), in those who did not receive post-ibrutinib therapy (n = 110), and in those who received post-ibrutinib therapy (n = 137) was 5.6 months (95% CI 3.8–8.7), 2.3 months (95% CI 1.2–3.9), and 8.7 months (95% CI 5.6–13.8), respectively. The most common adverse event during post-ibrutinib therapy was infection, with the use of anti-infectives (17%). Patients with MCL previously treated with ibrutinib have poor ability to carry out ADL and experience very poor outcomes. New safe, effective therapies are needed." @default.
- W4292297466 created "2022-08-19" @default.
- W4292297466 creator A5004550999 @default.
- W4292297466 creator A5016077305 @default.
- W4292297466 creator A5054366246 @default.
- W4292297466 creator A5069813415 @default.
- W4292297466 creator A5077829446 @default.
- W4292297466 creator A5081007817 @default.
- W4292297466 date "2022-08-19" @default.
- W4292297466 modified "2023-10-05" @default.
- W4292297466 title "Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database" @default.
- W4292297466 cites W1835355504 @default.
- W4292297466 cites W1984454461 @default.
- W4292297466 cites W2000006102 @default.
- W4292297466 cites W2007748783 @default.
- W4292297466 cites W2032482627 @default.
- W4292297466 cites W2040669551 @default.
- W4292297466 cites W2061326496 @default.
- W4292297466 cites W2067257663 @default.
- W4292297466 cites W2112023756 @default.
- W4292297466 cites W2146029333 @default.
- W4292297466 cites W2154066874 @default.
- W4292297466 cites W2162109567 @default.
- W4292297466 cites W2237195636 @default.
- W4292297466 cites W2310716991 @default.
- W4292297466 cites W2430862255 @default.
- W4292297466 cites W2470400696 @default.
- W4292297466 cites W2569849048 @default.
- W4292297466 cites W2617615285 @default.
- W4292297466 cites W2748428998 @default.
- W4292297466 cites W2760635695 @default.
- W4292297466 cites W2787916641 @default.
- W4292297466 cites W2788700819 @default.
- W4292297466 cites W2794404663 @default.
- W4292297466 cites W2811153307 @default.
- W4292297466 cites W2890354015 @default.
- W4292297466 cites W2891539827 @default.
- W4292297466 cites W2900472144 @default.
- W4292297466 cites W2912842263 @default.
- W4292297466 cites W2942273225 @default.
- W4292297466 cites W2975040754 @default.
- W4292297466 cites W2979956754 @default.
- W4292297466 cites W2995416368 @default.
- W4292297466 cites W3003221180 @default.
- W4292297466 cites W3014583893 @default.
- W4292297466 cites W3026138764 @default.
- W4292297466 cites W3029266545 @default.
- W4292297466 cites W3034609795 @default.
- W4292297466 cites W3093987483 @default.
- W4292297466 cites W3118314409 @default.
- W4292297466 cites W3119915771 @default.
- W4292297466 cites W3130396248 @default.
- W4292297466 cites W3134524629 @default.
- W4292297466 cites W3137447968 @default.
- W4292297466 cites W3144161037 @default.
- W4292297466 cites W3158081457 @default.
- W4292297466 cites W3160024593 @default.
- W4292297466 cites W3171413669 @default.
- W4292297466 cites W3184741685 @default.
- W4292297466 cites W3185036897 @default.
- W4292297466 cites W3194293108 @default.
- W4292297466 cites W3198713553 @default.
- W4292297466 cites W3212194761 @default.
- W4292297466 cites W3212609199 @default.
- W4292297466 cites W4200488914 @default.
- W4292297466 cites W4212936459 @default.
- W4292297466 cites W4241961579 @default.
- W4292297466 doi "https://doi.org/10.1007/s12325-022-02258-3" @default.
- W4292297466 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35984628" @default.
- W4292297466 hasPublicationYear "2022" @default.
- W4292297466 type Work @default.
- W4292297466 citedByCount "3" @default.
- W4292297466 countsByYear W42922974662023 @default.
- W4292297466 crossrefType "journal-article" @default.
- W4292297466 hasAuthorship W4292297466A5004550999 @default.
- W4292297466 hasAuthorship W4292297466A5016077305 @default.
- W4292297466 hasAuthorship W4292297466A5054366246 @default.
- W4292297466 hasAuthorship W4292297466A5069813415 @default.
- W4292297466 hasAuthorship W4292297466A5077829446 @default.
- W4292297466 hasAuthorship W4292297466A5081007817 @default.
- W4292297466 hasBestOaLocation W42922974661 @default.
- W4292297466 hasConcept C126322002 @default.
- W4292297466 hasConcept C143998085 @default.
- W4292297466 hasConcept C167135981 @default.
- W4292297466 hasConcept C2776694085 @default.
- W4292297466 hasConcept C2777525834 @default.
- W4292297466 hasConcept C2777938653 @default.
- W4292297466 hasConcept C2778461978 @default.
- W4292297466 hasConcept C2778715236 @default.
- W4292297466 hasConcept C2779338263 @default.
- W4292297466 hasConcept C2779878957 @default.
- W4292297466 hasConcept C2780653079 @default.
- W4292297466 hasConcept C2780775027 @default.
- W4292297466 hasConcept C2781442060 @default.
- W4292297466 hasConcept C41008148 @default.
- W4292297466 hasConcept C71924100 @default.
- W4292297466 hasConcept C77088390 @default.
- W4292297466 hasConceptScore W4292297466C126322002 @default.